Geron Corporation (NASDAQ: GERN) announced in September that Johnson & Johnson (NYSE: JNJ)'s Janssen unit opted to terminate a collaboration and licensing agreement between the companies for imetelstat, the former's myelofibrosis treatment candidate.
In reaction to the development, Geron stock slumped about 63 percent Sept. 27.
A Needham analyst sees the return of imetelstat as creating a buying opportunity in Geron.
Analyst Chad Messer upgraded Geron from Hold to Buy and introduced a $3 price target.
The J&J unit's decision to discontinue the tie-up with Geron came after the Phase 2 IMbark and IMerge studies in myelofibrosis, or MF, and myelodysplastic syndrome, or MDS, both of which established efficacy, Messer said in the Tuesday upgrade note.
Patients with low-risk MDS are an underserved market, as they are dependent on blood transfusions; high transfusion rates lead to poor outcomes in patients due to iron overload; and involve a higher financial burden, the analyst said.
Today's treatments include erythroid stimulating agents, which are effective only in the early stages of disease, he said.
In comparing Acceleron Pharma Inc (NASDAQ: XLRN)'s luspatercept and imetelstat, Messer said the latter will have superior efficacy in patients with a higher transfusion burden, thereby splitting the market by disease severity.
"We believe it is also possible that imetelstat will be used in patients progressing on luspatercept."
Geron expects to initiate a Phase 3 study in low-risk MDS by midyear, with a data readout expected in 2022, the analyst said.
Imetelstat has also demonstrated efficacy in MF patients failing frontline treatment with Jakafi, Messer said. The analyst expects an update on the path forward for MF in the third quarter of 2019.
"We believe the negative optics of a big pharma passing on imetelstat, and not a fundamental issue with the drug itself, have created a buying opportunity for GERN shares."
The Price Action
Geron shares were trading higher by 7.07 percent at $1.97 at the time of publication Tuesday.
FDA Rejects Regulatory Filing For Zogenix Epilepsy Drug; GW Pharma Moves In Sympathy
Latest Ratings for GERN
|Feb 2019||BTIG Research||Initiates Coverage On||Buy|
|Jan 2019||B. Riley FBR||Upgrades||Neutral||Buy|
View More Analyst Ratings for GERN
View the Latest Analyst Ratings
See more from Benzinga
- Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO
- The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.